Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma
- 24 September 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 24 (15), 2408-2412
- https://doi.org/10.1097/qad.0b013e32833db989
Abstract
In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. The use of protease inhibitors was independently associated with WHO grade III-IV neutropenia. Moreover, an inverse correlation between dosage of ritonavir and mean nadir neutrophil count was found. The concomitant administration of vinblastine-containing chemotherapy regimens with protease inhibitors can lead to higher levels of neutropenia than those of different classes of drugs such as nonnucleoside reverse transcriptase inhibitors or integrase inhibitorsKeywords
This publication has 20 references indexed in Scilit:
- Safety and Efficacy of Raltegravir in HIV-Infected Transplant Patients Cotreated with Immunosuppressive DrugsAmerican Journal of Transplantation, 2009
- Evolving epidemiology of malignancies in HIVCurrent Opinion in Oncology, 2008
- Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphomaHaematologica, 2007
- Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV‐associated Hodgkin's diseaseEuropean Journal of Haematology, 2007
- Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's diseaseEuropean Journal of Haematology, 2006
- Interactions Between Antiretrovirals and Antineoplastic Drug TherapyClinical Pharmacokinetics, 2005
- Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus‐associated Hodgkin's diseaseBritish Journal of Haematology, 2004
- Lopinavir/RitonavirDrugs, 2003
- Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infectionBlood, 2002
- Chemotherapy Consisting of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine With Granulocyte–Colony-Stimulating Factor in HIV-Infected Patients With Newly Diagnosed Hodgkin's Disease: A Prospective, Multi-institutional AIDS Clinical Trials Group Study (ACTG 149)JAIDS Journal of Acquired Immune Deficiency Syndromes, 2000